Vaccines against respiratory syncytial virus (RSV) initially provided strong protection, but that shielding dropped over time, researchers said in a new paper.
Among adults aged at least 60, a vaccine provided 71 percent protection against RSV infection at four months, Kersten Bartlet and other researchers said in a paper published on Aug. 19 by Epic Systems Corporation. The shielding dropped to 40 percent by month 19.
Protection against hospitalization declined from 73 percent at four months to 44 percent by month 19, according to the paper.
“These findings suggest that while protection against severe outcomes persists into the next season, it is significantly reduced compared to the initial vaccination season,” the authors stated….